Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A personalized melanoma vaccine enters a Phase III study, while a pancreatic cancer vaccine moves on to Phase II.
Moderna and Merck’s customized neoantigen vaccine plus Keytruda lowered the risk for metastasis or death by 65%.
Since 2020, there has been a nationwide shortage of the bladder cancer therapy Bacillus Calmette Guérin (BCG). Here’s why.
A personalized cancer vaccine plus Keytuda lowered the risk of melanoma coming back after surgery.
Keytruda can activate T cells that harbor latent HIV, a possible step toward a functional cure.
Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.
Another vaccine, from Novavax, was 89% effective in a U.K. trial, but both were less potent against the South African coronavirus mutation.
Keytruda plus chemotherapy reduced the risk of disease progression or death by 35% compared with chemotherapy alone in certain people.
Couric has partnered with Merck to produce a web series about being treated for cancer during the pandemic.
The American Red Cross and the American Cancer Society come together to encourage people to #GiveBloodtoGiveTime.
Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.
Adding immunotherapy to preoperative chemotherapy increased the likelihood of complete remission.
New immunotherapy option approved for uncommon, aggressive type of lung cancer.
First-line immunotherapy improved overall survival by around 20% to 40%, depending on PD-L1 level.
The immunotherapy led to an improvement in survival for people with gastric or gastroesophageal junction cancers with a high PD-L1 level.
The immunotherapy drug shows the most benefit for newly treated people with tumors that test positive for the PD-L1 biomarker.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.